Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 1, 2026 (6 months ago)

Blemish Spot Treatment

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Stability Specifications

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Blemish Spot Treatment (Salicylic Acid) 1%, .5 fl oz (15 ml) bottles, Skin Script, Chandler, AZ 85226, UPC 6 10563 13873 9.

Recalling firm
Island Kinetics, Inc. d.b.a. CoValence Laboratories
Origin
AZ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0487-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other recalls by Island Kinetics, Inc. d.b.a. CoValence Laboratories

All 2026 recalls
Class III · Low risk

Skin Rehab

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-04 D-0481-2026
Class III · Low risk

Remedy Gel

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-12 D-0480-2026

Other stability / shelf life recalls from 2026

All stability / shelf life recalls
Class III · Low risk

Revcovi (elapegademase-lvlr)

Failed Stability Specifications: Out of specification stability result for the protein concentration profile.

Ongoing Stability / shelf life Chiesi USA, Inc. NDC 10122-502-01 D-0838-2026